Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Liabilities and Shareholders Equity (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $53.0 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 17.28% to $53.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $121.8 million through Dec 2025, down 55.44% year-over-year, with the annual reading at $53.0 million for FY2025, 17.28% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $53.0 million at Spruce Biosciences, up from $15.3 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $139.1 million in Q1 2023, with the low at $15.3 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 4 years is $79.9 million, with a median of $86.6 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity rose 21.36% in 2023, then tumbled 76.48% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $85.6 million in 2022, then rose by 21.36% to $103.9 million in 2023, then crashed by 56.51% to $45.2 million in 2024, then grew by 17.28% to $53.0 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $53.0 million, $15.3 million, and $21.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.